Ítem
Acceso Abierto

Tamoxifen treatment of breast cancer cells : Impact on Hedgehog/GLI1 signaling

Mostrar el registro sencillo de la publicación
dc.creatorVillegas Gálvez, Victoria Eugenia
dc.creatorRondón Lagos, Milena
dc.creatorAnnaratone, Laura
dc.creatorCastellano, isabella
dc.creatorGrismaldo, Adriana
dc.creatorSapino, Anna
dc.creatorZaphiropoulos, Peter
dc.creator.googleVillegas, Victoria E.spa
dc.creator.googleRondón-Lagos, Milenaspa
dc.creator.googleAnnaratone, Lauraspa
dc.creator.googleCastellano, Isabellaspa
dc.creator.googleGrismaldo, Adrianaspa
dc.creator.googleSapino, Annaspa
dc.creator.googleZaphiropoulos, Peter G.spa
dc.date.accessioned2020-04-01T15:25:42Z
dc.date.available2020-04-01T15:25:42Z
dc.date.created2016
dc.date.issued2016
dc.description.abstractThe selective estrogen receptor (ER) modulator tamoxifen (TAM) has become the standard therapy for the treatment of ER+ breast cancer patients. Despite the obvious benefits of TAM, a proportion of patients acquire resistance to treatment, and this is a significant clinical problem. Consequently, the identification of possible mechanisms involved in TAM-resistance should help the development of new therapeutic targets. In this study, we present in vitro data using a panel of different breast cancer cell lines and demonstrate the modulatory effect of TAM on cellular proliferation and expression of Hedgehog signaling components, including the terminal effector of the pathway, the transcription factor GLI1. A variable pattern of expression following TAM administration was observed, reflecting the distinctive properties of the ER+ and ER´ cell lines analyzed. Remarkably, the TAM-induced increase in the proliferation of the ER+ ZR-75-1 and BT474 cells parallels a sustained upregulation of GLI1 expression and its translocation to the nucleus. These findings, implicating a TAM-GLI1 signaling cross-talk, could ultimately be exploited not only as a means for novel prognostication markers but also in efforts to effectively target breast cancer subtypes. © 2016 by the authors; licensee MDPI, Basel, Switzerland.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.3390/ijms17030308
dc.identifier.issn1661-6596
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/21353
dc.language.isoengspa
dc.relation.citationIssueNo. 3
dc.relation.citationTitleInternational Journal of Molecular Sciences
dc.relation.citationVolumeVol. 17
dc.relation.ispartofInternational Journal of Molecular Sciences, ISSN: 1661-6596 Vol. 17, No. 3 (2016)spa
dc.relation.urihttps://www.mdpi.com/1422-0067/17/3/308spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subjectHormona antineoplásicaspa
dc.subjectProteína GLI1spa
dc.subjectTamoxifeno factor de transcripcionspa
dc.subjectFactor de transcripción Gli1spa
dc.subjectCancer de mamaspa
dc.subject.ddcEnfermedadesspa
dc.subject.keywordSonic hedgehog proteinspa
dc.subject.keywordhumaneng
dc.subject.keywordAntineoplastic hormone agonists and antagonistsspa
dc.subject.keywordGLI1 proteineng
dc.subject.keywordSonic hedgehog proteinspa
dc.subject.keywordTranscription factorspa
dc.subject.keywordTranscription factor Gli1spa
dc.subject.lembNeoplasiasspa
dc.subject.lembTamoxifenospa
dc.titleTamoxifen treatment of breast cancer cells : Impact on Hedgehog/GLI1 signalingspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Tamoxifen_treatment_of_breast_cancer_cells.pdf
Tamaño:
3.87 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos